7,200 Shares in Revolution Medicines, Inc. $RVMD Purchased by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC bought a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) during the 2nd quarter, Holdings Channel reports. The firm bought 7,200 shares of the company’s stock, valued at approximately $1,348,000.

A number of other hedge funds also recently added to or reduced their stakes in RVMD. Nextech Invest Ltd. boosted its stake in shares of Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after acquiring an additional 1,304,347 shares in the last quarter. Millennium Management LLC increased its stake in Revolution Medicines by 681.8% in the 1st quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock valued at $5,529,000 after purchasing an additional 136,353 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Revolution Medicines by 14.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock valued at $10,615,000 after purchasing an additional 37,345 shares in the last quarter. Invesco Ltd. raised its holdings in Revolution Medicines by 19.3% during the second quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock worth $8,352,000 after purchasing an additional 36,760 shares during the last quarter. Finally, Jump Financial LLC raised its holdings in Revolution Medicines by 87.9% during the second quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock worth $561,000 after purchasing an additional 7,137 shares during the last quarter. 94.34% of the stock is owned by hedge funds and other institutional investors.

Key Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
• Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
• Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
• Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
• Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

Revolution Medicines Price Performance

RVMD stock opened at $221.15 on Friday. Revolution Medicines, Inc. has a 1 year low of $37.56 and a 1 year high of $224.31. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. The stock’s 50 day moving average price is $192.43 and its 200 day moving average price is $148.17. The firm has a market cap of $47.40 billion, a P/E ratio of -25.07 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period in the prior year, the firm earned ($1.31) earnings per share. On average, sell-side analysts expect that Revolution Medicines, Inc. will post -8.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on RVMD shares. Raymond James Financial reissued a “strong-buy” rating and issued a $248.00 target price on shares of Revolution Medicines in a report on Thursday. TD Cowen raised Revolution Medicines to a “strong-buy” rating in a research note on Monday. Oppenheimer boosted their price objective on shares of Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a research report on Thursday. Piper Sandler increased their price objective on shares of Revolution Medicines to $172.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada raised their target price on shares of Revolution Medicines from $203.00 to $251.00 and gave the company an “outperform” rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $193.28.

Insider Buying and Selling at Revolution Medicines

In related news, COO Margaret A. Horn sold 29,600 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $160.12, for a total transaction of $4,739,552.00. Following the sale, the chief operating officer owned 154,647 shares of the company’s stock, valued at $24,762,077.64. This trade represents a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Sushil Patel sold 5,580 shares of Revolution Medicines stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $187.99, for a total value of $1,048,984.20. Following the sale, the director owned 21,656 shares of the company’s stock, valued at approximately $4,071,111.44. This represents a 20.49% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 212,497 shares of company stock valued at $38,206,486. 7.60% of the stock is owned by company insiders.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.